Jasper Retained Earnings from 2010 to 2024

JSPR Stock

USD 22.31 0.09 0.40%

Jasper Therapeutics Retained Earnings yearly trend continues to be relatively stable with very little volatility. Retained Earnings are likely to grow to about -161.1 M this year. Retained Earnings is the cumulative amount of net income that Jasper Therapeutics retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. View All Fundamentals

Retained Earnings

First Reported

2019-12-31

Previous Quarter

-197.9 M

Current Value

-216.5 M

Quarterly Volatility

73.1 M

Covid

Check Jasper Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Jasper Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.2 M, Interest Expense of 8.4 M or Selling General Administrative of 11.2 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.1. Jasper financial statements analysis is a perfect complement when working with Jasper Therapeutics Valuation or Volatility modules.

Check out the analysis of Jasper Therapeutics Correlation against competitors.

To learn how to invest in Jasper Stock, please use our How to Invest in Jasper Therapeutics guide.

Latest Jasper Therapeutics' Retained Earnings Growth Pattern

Below is the plot of the Retained Earnings of Jasper Therapeutics over the last few years. It is the cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. Jasper Therapeutics' Retained Earnings historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Jasper Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported (169.6 M)

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Retained Earnings

Timeline

Jasper Retained Earnings Regression Statistics

	Arithmetic Mean	(39,437,200)
	Coefficient Of Variation	(149.43)
	Mean Deviation	46,074,160
	Median	(5,144,000)
	Standard Deviation	58,929,194
	Sample Variance	3472.6T
	Range	164.5M
	R-Value	(0.79)
	Mean Square Error	1392.9T
	R-Squared	0.63
	Significance	0.0004
	Slope	(10,438,407)
	Total Sum of Squares	48617.1T

Jasper Retained Earnings History

	2024	-161.1 M
	2023	-169.6 M
	2022	-105.1 M
	2021	-67.5 M
	2020	-36.8 M

Other Fundumenentals of Jasper Therapeutics

Retained Earnings Total Equity

Jasper Therapeutics Retained Earnings component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Short Term Investments	Capital Surpluse	Total Liab	Long Term Investments	Total Current Assets	Common Stock	Long Term Debt	Net Receivables	Long Term Debt Total	Net Invested Capital	Capital Stock	Net Working Capital	Property Plant Equipment	Current Deferred Revenue	Short Term Debt
Total Assets		0.83	-0.79	-0.96	-0.81	0.98	-0.53	0.92	0.29	0.7	1.0	-0.7	-0.53	-0.74	-0.53	0.97	0.58	1.0	0.96	-0.53	0.66
Total Stockholder Equity	0.83		-0.63	-0.9	-0.73	0.73	-0.68	0.73	-0.18	0.69	0.84	-0.39	-0.68	-0.7	-0.68	0.82	0.45	0.83	0.81	-0.68	0.66
Net Tangible Assets	-0.79	-0.63		0.72	0.94	-0.82	0.56	-0.94	-0.39	-0.71	-0.76	0.83	0.56	0.61	0.56	-0.9	-0.61	-0.78	-0.83	0.56	-0.93
Net Debt	-0.96	-0.9	0.72		0.84	-0.93	0.72	-0.82	-0.23	-0.77	-0.96	0.68	0.72	0.81	0.72	-0.92	-0.48	-0.97	-0.92	0.72	-0.66
Retained Earnings	-0.81	-0.73	0.94	0.84		-0.85	0.81	-0.87	-0.39	-0.86	-0.79	0.87	0.81	0.78	0.81	-0.89	-0.46	-0.83	-0.83	0.81	-0.94
Accounts Payable	0.98	0.73	-0.82	-0.93	-0.85		-0.55	0.91	0.48	0.71	0.97	-0.82	-0.55	-0.75	-0.55	0.96	0.56	0.98	0.95	-0.55	0.67
Short Term Investments	-0.53	-0.68	0.56	0.72	0.81	-0.55		-0.45	-0.19	-0.85	-0.53	0.63	1.0	0.77	1.0	-0.57	-0.07	-0.58	-0.53	1.0	-0.73
Capital Surpluse	0.92	0.73	-0.94	-0.82	-0.87	0.91	-0.45		0.33	0.62	0.89	-0.75	-0.45	-0.59	-0.45	0.97	0.73	0.9	0.95	-0.45	0.8
Total Liab	0.29	-0.18	-0.39	-0.23	-0.39	0.48	-0.19	0.33		0.2	0.26	-0.79	-0.19	-0.2	-0.19	0.33	0.25	0.34	0.34	-0.19	0.19
Long Term Investments	0.7	0.69	-0.71	-0.77	-0.86	0.71	-0.85	0.62	0.2		0.7	-0.66	-0.85	-0.97	-0.85	0.7	-0.01	0.7	0.59	-0.85	0.83
Total Current Assets	1.0	0.84	-0.76	-0.96	-0.79	0.97	-0.53	0.89	0.26	0.7		-0.66	-0.53	-0.75	-0.53	0.96	0.55	0.99	0.95	-0.53	0.63
Common Stock	-0.7	-0.39	0.83	0.68	0.87	-0.82	0.63	-0.75	-0.79	-0.66	-0.66		0.63	0.61	0.63	-0.77	-0.46	-0.73	-0.74	0.63	-0.72
Long Term Debt	-0.53	-0.68	0.56	0.72	0.81	-0.55	1.0	-0.45	-0.19	-0.85	-0.53	0.63		0.77	1.0	-0.57	-0.07	-0.58	-0.53	1.0	-0.73
Net Receivables	-0.74	-0.7	0.61	0.81	0.78	-0.75	0.77	-0.59	-0.2	-0.97	-0.75	0.61	0.77		0.77	-0.69	0.06	-0.74	-0.59	0.77	-0.7
Long Term Debt Total	-0.53	-0.68	0.56	0.72	0.81	-0.55	1.0	-0.45	-0.19	-0.85	-0.53	0.63	1.0	0.77		-0.57	-0.07	-0.58	-0.53	1.0	-0.73
Net Invested Capital	0.97	0.82	-0.9	-0.92	-0.89	0.96	-0.57	0.97	0.33	0.7	0.96	-0.77	-0.57	-0.69	-0.57		0.68	0.97	0.98	-0.57	0.78
Capital Stock	0.58	0.45	-0.61	-0.48	-0.46	0.56	-0.07	0.73	0.25	-0.01	0.55	-0.46	-0.07	0.06	-0.07	0.68		0.59	0.76	-0.07	0.36
Net Working Capital	1.0	0.83	-0.78	-0.97	-0.83	0.98	-0.58	0.9	0.34	0.7	0.99	-0.73	-0.58	-0.74	-0.58	0.97	0.59		0.97	-0.58	0.65
Property Plant Equipment	0.96	0.81	-0.83	-0.92	-0.83	0.95	-0.53	0.95	0.34	0.59	0.95	-0.74	-0.53	-0.59	-0.53	0.98	0.76	0.97		-0.53	0.67
Current Deferred Revenue	-0.53	-0.68	0.56	0.72	0.81	-0.55	1.0	-0.45	-0.19	-0.85	-0.53	0.63	1.0	0.77	1.0	-0.57	-0.07	-0.58	-0.53		-0.73
Short Term Debt	0.66	0.66	-0.93	-0.66	-0.94	0.67	-0.73	0.8	0.19	0.83	0.63	-0.72	-0.73	-0.7	-0.73	0.78	0.36	0.65	0.67	-0.73

Click cells to compare fundamentals

About Jasper Therapeutics Financial Statements

Jasper Therapeutics shareholders use historical fundamental indicators, such as Retained Earnings, to determine how well the company is positioned to perform in the future. Although Jasper Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Jasper Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Jasper Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Retained Earnings	-169.6 M	-161.1 M
Retained Earnings Total Equity	-94.6 M	-89.9 M

Pair Trading with Jasper Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Jasper Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Jasper Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Jasper Stock

0.72	IMAB	I Mab	Pair Corr
0.51	GNFT	Genfit	Pair Corr
0.47	LLY	Eli Lilly	Pair Corr
0.47	PFE	Pfizer Inc Fiscal Year End 4th of February 2025	Pair Corr
0.4	FLGC	Flora Growth Corp	Pair Corr

The ability to find closely correlated positions to Jasper Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Jasper Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Jasper Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Jasper Therapeutics to buy it.

The correlation of Jasper Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Jasper Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Jasper Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Jasper Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Jasper Stock Analysis

When running Jasper Therapeutics' price analysis, check to measure Jasper Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jasper Therapeutics is operating at the current time. Most of Jasper Therapeutics' value examination focuses on studying past and present price action to predict the probability of Jasper Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jasper Therapeutics' price. Additionally, you may evaluate how the addition of Jasper Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC